microRNA based prognostic biomarkers in pancreatic Cancer

Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Shixiang, Fesler, Andrew, Wang, Huaizhi, Ju, Jingfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963153/
https://www.ncbi.nlm.nih.gov/pubmed/29942514
http://dx.doi.org/10.1186/s40364-018-0131-1
_version_ 1783325002548903936
author Guo, Shixiang
Fesler, Andrew
Wang, Huaizhi
Ju, Jingfang
author_facet Guo, Shixiang
Fesler, Andrew
Wang, Huaizhi
Ju, Jingfang
author_sort Guo, Shixiang
collection PubMed
description Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC.
format Online
Article
Text
id pubmed-5963153
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59631532018-06-25 microRNA based prognostic biomarkers in pancreatic Cancer Guo, Shixiang Fesler, Andrew Wang, Huaizhi Ju, Jingfang Biomark Res Review Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC. BioMed Central 2018-05-21 /pmc/articles/PMC5963153/ /pubmed/29942514 http://dx.doi.org/10.1186/s40364-018-0131-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Guo, Shixiang
Fesler, Andrew
Wang, Huaizhi
Ju, Jingfang
microRNA based prognostic biomarkers in pancreatic Cancer
title microRNA based prognostic biomarkers in pancreatic Cancer
title_full microRNA based prognostic biomarkers in pancreatic Cancer
title_fullStr microRNA based prognostic biomarkers in pancreatic Cancer
title_full_unstemmed microRNA based prognostic biomarkers in pancreatic Cancer
title_short microRNA based prognostic biomarkers in pancreatic Cancer
title_sort microrna based prognostic biomarkers in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963153/
https://www.ncbi.nlm.nih.gov/pubmed/29942514
http://dx.doi.org/10.1186/s40364-018-0131-1
work_keys_str_mv AT guoshixiang micrornabasedprognosticbiomarkersinpancreaticcancer
AT feslerandrew micrornabasedprognosticbiomarkersinpancreaticcancer
AT wanghuaizhi micrornabasedprognosticbiomarkersinpancreaticcancer
AT jujingfang micrornabasedprognosticbiomarkersinpancreaticcancer

Ejemplares similares